SYNGENE Q4 FY26 Guidance vs Delivery (SYNGENE Management Mirror)

Revenue Outlook

In the Mar'26 Qtr, management introduced FY27 guidance, projecting broadly flat overall revenue heavily impacted by Librella destocking and geopolitical uncertainties, with no incremental Librella volumes expected in the Jun'26 and Sep'26 quarters. The fiscal year is expected to begin on a muted note, with a meaningfully stronger second half as new contracts ramp up, while sustained growth is projected to resume from FY28. The revenue split between Research Services and CDMO is expected to remain steady at two-thirds to one-third for FY27. Previously, in the Dec'25 Qtr, management expected high single-digit constant currency growth for FY25, underpinned by stable US biotech funding. No guidance was available for the Sep'25 Qtr. [Status: Initiated]